Presenter Status
Fellow
Abstract Type
Research
Primary Mentor
Shawn D. St Peter, MD
Start Date
14-5-2021 11:30 AM
End Date
14-5-2021 1:30 PM
Presentation Type
Poster Presentation
Description
Background: Infliximab has been shown to be effective in achieving clinical remission in patients with ulcerative colitis (UC) refractory to conventional therapy. However, there is conflicting data in the literature regarding its effectiveness as rescue therapy in acute severe colitis. Furthermore, most studies were conducted in adults, and pediatric onset of inflammatory bowel disease (IBD) is associated with more severe disease that may be less amenable to rescue therapy.
Objectives/Goal: We reviewed our experience with pediatric severe colitis and report outcomes following attempted rescue therapy with infliximab.
Methods/Design: A retrospective review was conducted of patients with UC or indeterminate colitis who received rescue infliximab therapy at our institution from January 2000-January 2019. Rescue infliximab therapy was considered if a child failed non-biologic therapy or progressed to fulminant or toxic colitis. Primary outcome was failed therapy resulting in colectomy. Secondary outcomes included number of admissions, antibiotic utilization, total parental nutrition (TPN) days, number of blood transfusions, imaging, number of laboratory tests, days of intravenous steroids, and length of stay. Statistical analysis was performed using STATA and a p-value of <0.05 determined significance.
Results: Thirty patients met inclusion criteria. The median age at administration of rescue infliximab treatment was 14.5 years [IQR 13, 17]. Rescue therapy with infliximab was successful in 33% (n=10), while 67% (n=20) underwent colectomy. Comparisons of clinical characteristics of those with successful infliximab rescue versus those who underwent colectomy are shown in Table 1. Children on maintenance steroids were less likely to have successful rescue with infliximab and require colectomy (p=0.03). Possibly indicative of rescue therapy, children requiring colectomy had a longer hospital stay (p=0.03), more abdominal radiographs (p=0.01), and were on a longer duration of antibiotics (p=<0.01) compared to children who were successfully rescued with infliximab. There was no difference between children successfully salvaged with infliximab and those who required colectomy with regards to vital signs or lab abnormalities, specifically white blood cell count and electrolyte values.
Conclusions: Infliximab as rescue therapy is ineffective in two-thirds of pediatric patients with severe colitis and does not have the potential for long-term cure. A response is more likely when patients are not on steroids at the time of admission.
MeSH Keywords
Infliximab; Length of Stay; Colitis, Ulcerative; Retrospective Studies; Anti-Bacterial Agents; Colectomy; Colitis; Inflammatory Bowel Diseases; Steroids
Included in
Gastroenterology Commons, Pediatrics Commons, Surgery Commons, Surgical Procedures, Operative Commons, Therapeutics Commons
Infliximab as Rescue Therapy in Pediatric Severe Colitis
Background: Infliximab has been shown to be effective in achieving clinical remission in patients with ulcerative colitis (UC) refractory to conventional therapy. However, there is conflicting data in the literature regarding its effectiveness as rescue therapy in acute severe colitis. Furthermore, most studies were conducted in adults, and pediatric onset of inflammatory bowel disease (IBD) is associated with more severe disease that may be less amenable to rescue therapy.
Objectives/Goal: We reviewed our experience with pediatric severe colitis and report outcomes following attempted rescue therapy with infliximab.
Methods/Design: A retrospective review was conducted of patients with UC or indeterminate colitis who received rescue infliximab therapy at our institution from January 2000-January 2019. Rescue infliximab therapy was considered if a child failed non-biologic therapy or progressed to fulminant or toxic colitis. Primary outcome was failed therapy resulting in colectomy. Secondary outcomes included number of admissions, antibiotic utilization, total parental nutrition (TPN) days, number of blood transfusions, imaging, number of laboratory tests, days of intravenous steroids, and length of stay. Statistical analysis was performed using STATA and a p-value of <0.05 determined significance.
Results: Thirty patients met inclusion criteria. The median age at administration of rescue infliximab treatment was 14.5 years [IQR 13, 17]. Rescue therapy with infliximab was successful in 33% (n=10), while 67% (n=20) underwent colectomy. Comparisons of clinical characteristics of those with successful infliximab rescue versus those who underwent colectomy are shown in Table 1. Children on maintenance steroids were less likely to have successful rescue with infliximab and require colectomy (p=0.03). Possibly indicative of rescue therapy, children requiring colectomy had a longer hospital stay (p=0.03), more abdominal radiographs (p=0.01), and were on a longer duration of antibiotics (p=<0.01) compared to children who were successfully rescued with infliximab. There was no difference between children successfully salvaged with infliximab and those who required colectomy with regards to vital signs or lab abnormalities, specifically white blood cell count and electrolyte values.
Conclusions: Infliximab as rescue therapy is ineffective in two-thirds of pediatric patients with severe colitis and does not have the potential for long-term cure. A response is more likely when patients are not on steroids at the time of admission.
Comments
Abstract Only.